[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-widespread-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-widespread-pain":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,79,101,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100609303","the-added-value-of-transcranial-direct-current-stimulation-tdcs-during-exercise-for-people-with-chronic-widespread-pain-100609303",false,"NCT07212829","The Added Value of Transcranial Direct Current Stimulation (tDCS) During Exercise for People With Chronic Widespread Pain","Unravelling the Epigenetic Mechanisms of Exercise-induced Pain in Chronic Widespread Pain: DNA Methylation Regulation of the Brain-derived Neurotrophic Factor Expression and Its Modulation by Transcranial Direct Current Stimulation","Inclusion Criteria:\n\nPatients\n\nParticipants in the patient group must meet all of the following criteria:\n\n1. Diagnosis of chronic widespread pain (CWP) or fibromyalgia;\n2. Age between 18 and 70 years old;\n3. Body mass index (BMI) ≤ 35;\n4. Widespread Pain Index (WPI) assessment: the WPI questionnaire (0-19 points) will be used to record the number and distribution of painful body sites. Participants will be classified as having CWP if pain is reported on both sides of the body, above and below the waist, and in the axial skeleton, with pain symptoms lasting ≥ 3 months;\n5. Stable medication use for at least 1 month prior to study entry.\n\nHealthy control group\n\nParticipants in the healthy control group must meet all of the following criteria:\n\n1. Age between 18 and 70 years old;\n2. Body mass index (BMI) ≤ 35;\n3. No chronic conditions, such as chronic pain and diabetes.\n\nExclusion Criteria:\n\nFor both patients and healthy controls, participants will be excluded if they meet any of the following:\n\n1. Current pregnancy or pregnancy within the past 12 months;\n2. Contraindications for non-invasive brain stimulation (NIBS), in line with published safety guidelines;\n3. History of neurological disorders, including epilepsy (personal or family history), traumatic brain injury, stroke, dementia, or Parkinson's disease;\n4. Major medical conditions, including cancer, endocrine or metabolic disorders, urine, genital and cardiovascu-lar diseases (e.g., myocardial infarction, heart failure, arrhythmia, uncontrolled hypertension).\n5. Substance abuse.\n6. Presence of psychiatric disorders other than depression or anxiety.",true,"ALL","18 Years","70 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25],"NA","Many people with chronic widespread pain (CWP) feel more pain and fatigue after exercise. This makes it hard to stay active. Unfortunately, the investigators do not fully understand why this happens and how to prevent it.\n\nThe primary goal of this study is to explore the underlying genetic and epigenetic mechanisms of BDNF gene in response to exercise, and investigate if transcranial direct current stimulation (tDCS) during exercise works to improve worsening symptoms response to exercise in people with CWP.\n\nThe investigators designed a randomized crossover study and will enroll 60 patients with CWP and 60 healthy controls. Participants will undergo 2 interventions in random order: 1) exercise + active tDCS, and 2) exercise + sham tDCS. Participants will visit the hospital twice with at least one week in between the visits.",[28,29],"Chronic Widespread Pain","Fibromyalgia (FM)",[31,32,33,34],"BDNF","pain","exercise","DNA methylation","RECRUITING","2026-04-14",{"date":38,"type":39},"2026-04-20","ACTUAL",{"date":41,"type":39},"2026-02-01",{"date":43,"type":22},"2028-06-30",{"name":45,"class":46},"Vrije Universiteit Brussel","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":16,"sex":55,"minAge":18,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":47},"100624935","comparison-of-multidimensional-parameters-in-women-with-fibromyalgia-and-healthy-controls-100624935","NCT07416097","Comparison of Multidimensional Parameters in Women With Fibromyalgia and Healthy Controls","Comparison of Symptoms, Psychological Status, Autonomic Function, Sleep, Eating Behaviors, and Gastrointestinal Parameters in Women With Fibromyalgia and Healthy Women: A Cross-Sectional Study","Inclusion Criteria\n\nFibromyalgia Group\n\n* Female participants aged between 18 and 65 years\n* Admitted to the Physical Medicine and Rehabilitation Unit of Buca Seyfi Demirsoy Training and Research Hospital\n* Voluntary participation and provision of written informed consent\n* Clinical diagnosis of fibromyalgia according to the 2016 American College of Rheumatology (ACR) criteria\n\nHealthy Control Group\n\n* Female participants aged between 18 and 65 years\n* Admitted to the Physical Medicine and Rehabilitation Unit of Buca Seyfi Demirsoy Training and Research Hospital\n* Voluntary participation and provision of written informed consent\n* No history or current diagnosis of chronic widespread pain, fibromyalgia, or any rheumatologic disease\n\nExclusion Criteria:\n\n* Severe reading or comprehension difficulties\n* Severe hearing impairment\n* Pregnancy\n* Presence of an active infection\n* Neurological or orthopedic conditions that limit mobility\n* Diagnosis of cancer\n* History of major surgery within the past 6 months\n* Presence of psychiatric or cognitive disorders that may interfere with study assessments","FEMALE","65 Years",{"count":58,"type":22},80,[25],"Fibromyalgia (FM) is a chronic, widespread pain syndrome affecting 2-6.6% of the population and significantly impairing quality of life. In addition to pain, individuals with FM commonly experience fatigue, sleep disturbances, cognitive and psychological problems, leading to functional limitations and social difficulties. Central sensitization is considered a key mechanism, although the exact pathophysiology remains unclear, highlighting the need for multidimensional assessment.\n\nFM affects not only physical function but also psychological status, autonomic nervous system regulation, sleep quality, self-esteem, eating behaviors, and gastrointestinal function. Depression, anxiety, autonomic dysfunction, sleep disorders, altered eating behaviors, and gastrointestinal symptoms are highly prevalent and closely associated with pain severity, fatigue, and reduced quality of life.\n\nGiven its complex biopsychosocial nature, FM requires a holistic evaluation and management approach. Accordingly, this study aims to compare symptoms, psychological status, autonomic function, sleep, eating behaviors, and gastrointestinal parameters between women with fibromyalgia and healthy women.",[62,28],"Fibromyalgia",[62,64,65,66,67,68],"Psychological Status","Autonomic Function","Sleep","Eating Behaviors","Gastrointestinal Parameters","NOT_YET_RECRUITING","2026-02-10",{"date":72,"type":39},"2026-02-17",{"date":74,"type":22},"2026-06-15",{"date":76,"type":22},"2027-06-15",{"name":78,"class":46},"Izmir Democracy University",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":16,"sex":17,"minAge":86,"maxAge":56,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":89,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100422977","chronic-widespread-pain-in-hiv-novel-mechanisms-and-therapeutics-100422977","NCT04787848","Chronic Widespread Pain in HIV: Novel Mechanisms and Therapeutics","Role of Endogenous Opioid Peptides in HIV-associated Chronic Widespread Pain","Inclusion Criteria:\n\n* Confirmed HIV diagnosis and currently a patient in the UAB 1917 HIV Clinic\n* Age 19 - 65; the lower end of this age range was chosen to capture young adults with HIV infection, and participants over 65 years are increasingly likely to meet one or more exclusion criteria\n* All people living with HIV must be currently receiving stable antiretroviral therapy (ART) for inclusion in this study\n* Non-HIV participants must be confirmed as HIV negative. HIV-negative participants with chronic widespread pain must self-report bodily pain more than once per week for at least three consecutive months and HIV-negative participants without chronic pain must self-report no pain, or pain less frequently than once per week for at least three consecutive months\n\nExclusion Criteria:\n\n* Anemia\n* Current or past history of blood disorders which may increase hemolysis\n* Active microbial infections which may alter the quantity or quality of blood inflammatory cells such as monocytes and neutrophils\n* Use of certain medication other than antiretroviral therapy that might conflict with study observations. However, participants will not be excluded or asked to withdraw from medications used for pain management since temporary withdrawal from these medications could affect pain measures (exceptions will be therapies such as methadone or buprenorphine used to treat opioid addiction). Only those who are stable on these medications for at least 60 days will be included. All patient medications used for at least the 60 days prior to participation will be recorded and controlled in statistical analyses as needed\n* Systemic rheumatic disease (e.g., rheumatoid arthritis, systemic lupus erythematosus). These rheumatologic conditions will be excluded due to their autoimmune characteristic. . Cachexia (wasting syndrome) and severe frailty. This exclusion is in place to protect against the stress of experimental pain testing\n* A history of clinically significant surgery in the past year\n* Uncontrolled hypertension (i.e. SBP\u002FDBP of \\>150\u002F95) or cardiovascular or peripheral arterial disease. These exclusions are in place primarily for safety reasons because the cold pressor task represents a cardiovascular challenge. However, uncontrolled hypertension can also affect pain perception, which is another reason for excluding these individuals\n* Poorly controlled diabetes (HbA1c \\> 8%) for both safety reasons, and because diabetic neuropathy could alter pain perception\n* Neurological disease (e.g. Parkinson's, multiple sclerosis, epilepsy)\n* Serious psychiatric disorder requiring hospitalization within the past 12 months or characterized by active suicidal ideation\n* Any participant deemed to be actively suicidal upon study screening will be escorted to the UAB emergency room and evaluated by the Psychiatry Service\n* Diminished cognitive function that would interfere with understanding of study procedures. The Realm Health Literacy Test will be administered to ensure that participants are free of cognitive impairment that would compromise study participation\n* Pregnancy. Inclusion\u002Fexclusion criteria will be verified using the screening tool in combination with review of participants' medical records","19 Years",{"count":88,"type":22},200,[25],"To determine if decreased production or release of endogenous opioid peptides by peripheral immune cells contributes to hypersensitivity in people with HIV",[28],"2026-01-13",{"date":94,"type":39},"2026-01-14",{"date":96,"type":39},"2021-11-15",{"date":98,"type":22},"2026-07-30",{"name":100,"class":46},"Florida International University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":56,"enrollmentInfo":109,"targetDuration":4,"studyType":23,"phases":111,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":47},"100614653","helping-lupus-patients-manage-fibromyalgia-symptoms-through-emotional-awareness-and-expression-therapy-eaet-100614653","NCT07282392","Helping Lupus Patients Manage Fibromyalgia Symptoms Through Emotional Awareness and Expression Therapy (EAET)","Evaluating the Feasibility and Efficacy of Emotional Awareness and Expression Therapy (EAET) on Fibromyalgia Outcomes in Patients With Systemic Lupus Erythematosus (SLE).","EAET","Inclusion Criteria:\n\n* Adults of all genders, ages 18-65.\n* A diagnosis of lupus and fibromyalgia or chronic widespread pain by a licensed rheumatologist\n* Be on a stable medication regimen.\n\nExclusion Criteria:\n\n* Serious psychiatric disorders (e.g., schizophrenia or bipolar disorder) uncontrolled with medications.\n* Active suicidal ideation.\n* Untreated alcohol or substance use disorder.\n* Substantial cognitive impairment.\n* Changes in medications in the past 3 months.\n* Enrollment in another treatment study.\n* Current involvement in health-related litigation or disability application.\n* Inability to use a computer and\u002For smartphone.\n* limited access to the internet.\n* Inability to communicate in English.\n* Failure to complete the baseline assessments.",{"count":110,"type":22},30,[25],"The goal of this clinical trial is to learn if a psychotherapy intervention works to relieve widespread pain in patients with lupus. The main questions it aims to answer are:\n\nIs the psychotherapy treatment safe for lupus patients? Are lupus patients able to complete the treatment? Can the treatment help improve chronic pain and other symptoms in lupus patients?\n\nResearchers will compare the treatment to a control (participants who will continue their medical treatment but will not receive psychotherapy for the time frame of the treatment) to see if the psychotherapy treatment works to relieve widespread pain and other lupus-related symptoms.\n\nParticipants will:\n\nFill out questionnaires before and after the treatment. Participate in 8 weekly treatment sessions, 2 hours per session, delivered via Zoom from their own home.\n\nKeep a list of medications and monitor any changes in their medication regimen.",[114,29,28],"Lupus",[116,117,118],"lupus","fibromyalgia","chronic widespread pain","2025-12-19",{"date":121,"type":39},"2025-12-29",{"date":123,"type":39},"2025-12-01",{"date":125,"type":22},"2028-11-04",{"name":127,"class":46},"University of Utah",{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":134,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":23,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":47},"100534551","neurofeedback-for-nociplastic-pain-in-rheumatoid-arthritis-nectar-100534551","NCT06240299","Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis (NECTAR)","Neurofeedback for Nociplastic Pain in Rheumatoid Arthritis","NECTAR","Inclusion Criteria:\n\n* Fulfilment of the ACR\u002FEULAR Classification Criteria for rheumatoid arthritis (RA)\n* Fulfilment of the American College of Rheumatology criteria for chronic widespread pain\n* Stable disease (swollen joint count ≤1 and CRP ≤10)\n* Has normal or corrected to normal vision and hearing abilities\n* Right-handed (to reduce baseline motor response test heterogeneity)\n* Pain intensity equal or larger than 4 on the Visual Numerical Scale (0 no pain, 10, max pain imaginable)\n\nExclusion Criteria:\n\n* Unable to understand the task.\n* Unable to provide a written informed consent.\n* Unable to understand English.\n* Major confounding neurological diseases including Multiple Sclerosis, Stroke, Traumatic Brain Injury, Parkinson's Disease, and Alzheimer's Disease)\n* Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in the study (psychosis, suicidal ideation etc)\n* Under active management of pain team (changing medications, other non pharmacological pain treatment)\n* Involved in other interventional experimental studies","75 Years",{"count":138,"type":22},16,[25],"Rheumatoid arthritis is an autoimmune condition, causing inflammation and pain. Yet pain may persist even when inflammation has been treated. This residual pain, called nociplastic pain, has symptoms of a chronic pain condition called fibromyalgia. There are few effective therapies to address this residual pain. Published literature shows that fibromyalgia can be treated by neurofeedback, a noninvasive method that is based on the voluntary modulation of cortical activity. In this pilot study, the investigators want to test the effect of neurofeedback on the fibromyalgia component of pain in rheumatoid arthritis, and also to investigate its effects on related symptoms such as fatigue and sleep disturbance.",[142,28],"Rheumatoid Arthritis","2025-06-11",{"date":145,"type":39},"2025-06-15",{"date":147,"type":39},"2024-06-24",{"date":149,"type":22},"2027-01-29",{"name":151,"class":46},"NHS Greater Glasgow and Clyde"]